Alzheon Initiates Open-Label Extensions for Phase 2 and 3 Studies of Alzheimer Agent ALZ-801
May 1st 2024Phase 2 biomarker trial participants who completed 156 weeks of treatment were offered enrollment into another 52-week extension to continue to observe safety, assessments of plasma biomarkers, and cognitive effects, among others.
Ocrelizumab Gains EU CHMP Positive Opinion for Subcutaneous Formulation to Treat MS
May 1st 2024In the phase 3 OCARINA 2 trial, subcutaneous ocrelizumab was non-inferior to intravenous infusion based on concentration levels in the blood, as well as comparable efficacy on relapses and brain lesions.
Latest Findings on AXS-05 Treatment for Agitation in Alzheimer Disease: Anton P. Porsteinsson, MD
May 1st 2024The director of the Alzheimer's Disease Care, Research and Education Program at the University of Rochester talked about recent results on the phase 3 ACCORD trial assessing AXS-05 for agitation in Alzheimer disease. [WATCH TIME: 8 minutes]
Applying the Innovation Biodesign Framework to Promote Equity and Green Activity in Dementia Care
Lassell et al present a use case demonstrating the process of moving an unmet need to the “solution space” of the Innovation Biodesign Framework for addressing a healthcare challenge in a specific at-risk population.
MOG-Antibody Testing and the Search for Effective Treatment in MOGAD: Eoin P. Flanagan, MB, BCh
April 30th 2024The professor of neurology at Mayo Clinic discussed the importance of standardizing MOG- antibody testing techniques and the need for effective treatments in patients living with MOGAD. [WATCH TIME: 3 minutes]
AI-Powered Neurotech Could Revolutionize Dementia Care and Unlock Communications
April 30th 2024Neal K. Shah, CEO of CareYaya Health Technologies, discussed how emerging neurotechnology, such as mobile EEG devices paired with customized AI and machine learning models, is poised to transform the fight against dementia.
Literature Review Demonstrates Ravulizumab’s Superior Efficacy Over Other Approved NMOSD Treatments
April 29th 2024In comparison to previously approved treatments like satralizumab and inebilizumab, ravulizumab-treated patients performed significant better on outcomes of first relapse and time to first relapse.
Understanding MOG-Antibody Associated Disease in Clinical Research: Eoin P. Flanagan, MB, BCh
April 29th 2024The professor of neurology at Mayo Clinic talked about MOG-antibody associated disease, a relatively newly recognized demyelinating condition of the central nervous system. [WATCH TIME: 4 minutes]
NeurologyLive® Clinician of the Month Spotlight: Kelly Papesh, DNP, APRN, FNP-BC
April 27th 2024As part of our monthly clinician spotlight, NeurologyLive® highlighted movement disorder expert Kelly Papesh, DNP, APRN, FNP-BC, executive director of the Association of Movement Disorder Advanced Practice Providers.
Expanding Access to CGRP Medications as First-Line Treatments: Thoughts and Implications
April 26th 2024Stephen Samples, MD, chair of Allegheny Health Network’s department of neurology, gave commentary towards the AHS’s recent statement paper addressing CGRP-targeting therapies as a first-line option for preventive migraine.